FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002028382> ?p ?o ?g. }

• W2002028382 endingPage "854" @default.
• W2002028382 startingPage "851" @default.
• W2002028382 abstract "Drugs that increase angiotensin 2 formation, including thiazides, calcium channel blockers, and angiotensin 2 type 1 (AT1) receptor blockers, may be more effective in stroke prevention than angiotensin 2 suppressive drugs such as angiotensin-converting enzyme inhibitors and beta-blockers.To assess whether angiotensin 2 formation increasing drugs reduce incident stroke severity compared with angiotensin 2 formation suppressive drugs.Consecutive patients presenting within 24 hours of first-ever ischemic stroke over an 18-month period were studied. Subjects were only included if they were on only angiotensin 2 formation increasers, only angiotensin 2 formation suppressors, or no antihypertensive agents. NIH Stroke Scale (NIHSS) score at presentation was used as the index of stroke severity. Demographic data, risk factors, admission blood pressures, other medications, and stroke mechanisms were controlled for across the three groups using least absolute deviation linear regression.One hundred seventy-five individuals met study criteria. Mean age was 67.4 years; 45% were women. Forty-nine patients were on angiotensin 2 formation suppressors and 16 on angiotensin 2 formation increasers. Age at admission, atrial fibrillation, previous antithrombotic use, cardioembolic and large-vessel atherosclerotic mechanisms, and mean systolic and diastolic blood pressure were significant univariate predictors of presenting median NIHSS score. On multivariate analysis, the adjusted median NIHSS score was lower in the angiotensin 2 increasers (median = 2.2; p = 0.005) and trended lower for angiotensin 2 suppressors (median = 4.4; p = 0.054) compared with the no-antihypertensive group (median = 6.0). There was no difference in stroke severity between angiotensin 2 increasers compared with angiotensin 2 suppressors (p = 0.123).Angiotensin 2 formation increasing agents did not reduce ischemic stroke severity more than angiotensin 2 formation suppressing agents. However, the prestroke use of antihypertensives was associated with reduced severity of incident ischemic strokes." @default.
• W2002028382 created "2016-06-24" @default.
• W2002028382 creator A5003065121 @default.
• W2002028382 creator A5016874614 @default.
• W2002028382 creator A5044695100 @default.
• W2002028382 creator A5052180681 @default.
• W2002028382 creator A5063432191 @default.
• W2002028382 creator A5063673987 @default.
• W2002028382 creator A5075359983 @default.
• W2002028382 date "2005-09-26" @default.
• W2002028382 modified "2023-09-23" @default.
• W2002028382 title "Angiotensin 2 type 2 receptor activity and ischemic stroke severity" @default.
• W2002028382 cites W1999525252 @default.
• W2002028382 cites W2011125535 @default.
• W2002028382 cites W2015180525 @default.
• W2002028382 cites W2041321282 @default.
• W2002028382 cites W2041702513 @default.
• W2002028382 cites W2051173446 @default.
• W2002028382 cites W2054442980 @default.
• W2002028382 cites W2057519653 @default.
• W2002028382 cites W2059923500 @default.
• W2002028382 cites W2062890486 @default.
• W2002028382 cites W2072849519 @default.
• W2002028382 cites W2077210270 @default.
• W2002028382 cites W2080504768 @default.
• W2002028382 cites W2088140015 @default.
• W2002028382 cites W2093072754 @default.
• W2002028382 cites W2118403271 @default.
• W2002028382 cites W2133811449 @default.
• W2002028382 cites W2138505333 @default.
• W2002028382 cites W2144638874 @default.
• W2002028382 cites W2144850799 @default.
• W2002028382 cites W2314494530 @default.
• W2002028382 cites W56491902 @default.
• W2002028382 doi "https://doi.org/10.1212/01.wnl.0000175984.29283.6d" @default.
• W2002028382 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16186522" @default.
• W2002028382 hasPublicationYear "2005" @default.
• W2002028382 type Work @default.
• W2002028382 sameAs 2002028382 @default.
• W2002028382 citedByCount "21" @default.
• W2002028382 countsByYear W20020283822012 @default.
• W2002028382 countsByYear W20020283822014 @default.
• W2002028382 countsByYear W20020283822015 @default.
• W2002028382 countsByYear W20020283822016 @default.
• W2002028382 countsByYear W20020283822018 @default.
• W2002028382 countsByYear W20020283822022 @default.
• W2002028382 crossrefType "journal-article" @default.
• W2002028382 hasAuthorship W2002028382A5003065121 @default.
• W2002028382 hasAuthorship W2002028382A5016874614 @default.
• W2002028382 hasAuthorship W2002028382A5044695100 @default.
• W2002028382 hasAuthorship W2002028382A5052180681 @default.
• W2002028382 hasAuthorship W2002028382A5063432191 @default.
• W2002028382 hasAuthorship W2002028382A5063673987 @default.
• W2002028382 hasAuthorship W2002028382A5075359983 @default.
• W2002028382 hasConcept C104849204 @default.
• W2002028382 hasConcept C126322002 @default.
• W2002028382 hasConcept C127413603 @default.
• W2002028382 hasConcept C144301174 @default.
• W2002028382 hasConcept C164705383 @default.
• W2002028382 hasConcept C27016395 @default.
• W2002028382 hasConcept C2779161974 @default.
• W2002028382 hasConcept C2780192228 @default.
• W2002028382 hasConcept C2780645631 @default.
• W2002028382 hasConcept C2908929049 @default.
• W2002028382 hasConcept C38180746 @default.
• W2002028382 hasConcept C71924100 @default.
• W2002028382 hasConcept C78519656 @default.
• W2002028382 hasConcept C84393581 @default.
• W2002028382 hasConceptScore W2002028382C104849204 @default.
• W2002028382 hasConceptScore W2002028382C126322002 @default.
• W2002028382 hasConceptScore W2002028382C127413603 @default.
• W2002028382 hasConceptScore W2002028382C144301174 @default.
• W2002028382 hasConceptScore W2002028382C164705383 @default.
• W2002028382 hasConceptScore W2002028382C27016395 @default.
• W2002028382 hasConceptScore W2002028382C2779161974 @default.
• W2002028382 hasConceptScore W2002028382C2780192228 @default.
• W2002028382 hasConceptScore W2002028382C2780645631 @default.
• W2002028382 hasConceptScore W2002028382C2908929049 @default.
• W2002028382 hasConceptScore W2002028382C38180746 @default.
• W2002028382 hasConceptScore W2002028382C71924100 @default.
• W2002028382 hasConceptScore W2002028382C78519656 @default.
• W2002028382 hasConceptScore W2002028382C84393581 @default.
• W2002028382 hasIssue "6" @default.
• W2002028382 hasLocation W20020283821 @default.
• W2002028382 hasLocation W20020283822 @default.
• W2002028382 hasOpenAccess W2002028382 @default.
• W2002028382 hasPrimaryLocation W20020283821 @default.
• W2002028382 hasRelatedWork W1991854388 @default.
• W2002028382 hasRelatedWork W2019984143 @default.
• W2002028382 hasRelatedWork W2022197230 @default.
• W2002028382 hasRelatedWork W2022842708 @default.
• W2002028382 hasRelatedWork W2034551019 @default.
• W2002028382 hasRelatedWork W2037731086 @default.
• W2002028382 hasRelatedWork W2048982602 @default.
• W2002028382 hasRelatedWork W2093949391 @default.
• W2002028382 hasRelatedWork W2412077388 @default.
• W2002028382 hasRelatedWork W2741586533 @default.
• W2002028382 hasVolume "65" @default.

• next